Adenocarcinoma of the Uterine Cervix.
- Author:
Eun Ji CHUNG
1
;
Hyun Soo SHIN
;
Hyung Sik LEE
;
Gwi Eon KIM
;
John J Kyu LOH
;
Chang Ok SUH
Author Information
1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Adenocarcinoma of cervix;
Tumor size;
Stage of the disease
- MeSH:
Adenocarcinoma*;
Cervix Uteri*;
Female;
Humans;
Incidence;
Prognosis;
Radiation Oncology;
Retrospective Studies;
Survival Rate;
Uterine Hemorrhage
- From:Journal of the Korean Society for Therapeutic Radiology
1991;9(2):277-284
- CountryRepublic of Korea
- Language:English
-
Abstract:
Survival data, prognostic factors, and patterns of failure were retrospectively analyzed for a total of 76 patients with adenocarcinoma of the uterine cervix treated between January 1981 and December 1987, which represents 4.1% of all primary cervical carcinomas treated, at Department of Radiation Oncology, Yensei Cancer Center, Yonsei University College of Medicine. The mean age of the patients was 49years(range, 27~79years) and the peak incidence was in the group 50 to 59years of age. More half of the patients were postmenopausal (46/76=60.5%). Most patients(76%)had abnormal vaginal bleeding either alone or in combination with other symptoms. The proportion of stage Iib was 43.4%. There were 4 major histologic subtypes: pure adenocarcinoma(48/76=63.2%), adenosquamous carcinoma(20/76=26.3%), papillary (5/76=6.6%) and clear cell carcinoma(3/76=3.9%). Of the many clinicopathologic variables evaluated for prognosis, the most significant prognostic factors were stage of disease and the size of tumor. The overall 5-year survival rate was 68%, and the 5-year survival rates for stage Ib, II and III were 90%, 66% and 54%, respectively. Control of pelvic tumors was achieved in 938%, 90.2% and 50.0% of cases of stage Ib, II and III disease, respectively. In present study, treatment modalities (radiation therapy alone/combined operative and radiation therapy) did not affect the local control of tumor and the survival.
